Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 5/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981354 | 0.94 | HPGD (0.58) | HPGDRECQLCYP11B2ACACBGRM5 | |
| SCHEMBL26131546 | 0.89 | HPGD (0.56) | HPGDRECQLCYP11B2ACACBGRM5 | |
| SCHEMBL6868004 | 0.86 | CYP11B2 (0.54) | HPGDCYP11B2ACACBSCD5HDAC2 | |
| SCHEMBL29663182 | 0.84 | HPGD (0.56) | HPGDRECQLGRM5EPHX2HSD17B10 | |
| SCHEMBL31717436 | 0.84 | HSD17B10 (0.47) | HPGDRECQLCYP11B2ACACBSCD5 | |
| SCHEMBL24697198 | 0.84 | CYP11B2 (0.48) | HPGDRECQLCYP11B2ACACBSCD5 | |
| SCHEMBL31705959 | 0.83 | HPGD (0.59) | HPGDRECQLCYP11B2ACACBGRM5 | |
| SCHEMBL2820688 | 0.83 | HPGD (0.72) | HPGDRECQLHSD17B10PREPUSP2 | |
| SCHEMBL23906185 | 0.83 | CYP11B2 (0.52) | HPGDCYP11B2ACACBSCD5HDAC2 | |
| SCHEMBL25275679 | 0.83 | CYP11B2 (0.52) | HPGDCYP11B2ACACBSCD5HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025010311-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |